HETEROGENEOUS DOCUMENTATION AND POOR CONCORDANCE OF NASH PATHOLOGY MAY LIMIT ITS CLINICAL UTILITY IN REAL-WORLD PRACTICE

被引：0

作者：

Kim, Hannah ^{[1
]}

Idowu, Michael O. ^{[2
]}

Zink, Richard C. ^{[3
]}

Mospan, Andrea ^{[3
]}

Roden, Michael ^{[4
]}

Newsome, Philip N. ^{[5
]}

Lok, Anna S. ^{[6
]}

Thuluvath, Paul J. ^{[7
,8
]}

Taunk, Jawahar L. ^{[9
]}

Fried, Michael W. ^{[3
]}

Sanyal, Arun J. ^{[10
]}

Barritt, Alfred Sidney ^{[1
]}

机构：

[1] Univ N Carolina, Chapel Hill, NC 27515 USA

[2] Virginia Commonwealth Univ, Pathol, Richmond, VA 23284 USA

[3] Target Pharmasolut Inc, Durham, NC USA

[4] Univ Hosp Dusseldorf, Dusseldorf, Germany

[5] Natl Inst Hlth Res, Birmingham Biomed Res Ctr, Birmingham, W Midlands, England

[6] Univ Michigan, Ann Arbor, MI 48109 USA

[7] Mercy Med Ctr, Med, Baltimore, MD USA

[8] Univ Maryland, Sch Med, College Pk, MD 20742 USA

[9] Adv Gastro Associates LLC, Palm Harbor, FL USA

[10] Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23284 USA

来源：

HEPATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1595

引用

页码：971 / 971

页数：1

共 28 条

[1] Examining Endpoint Concordance in Clinical Trials and Real-World Clinical Practice to Advance Real-World Evidence Utilization
Schaumberg, Debra
Larholt, Kay
Apgar, Elizabeth
Pashos, Chris L.
Hirsch, Gigi
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 472 - 475
[2] Examining Endpoint Concordance in Clinical Trials and Real-World Clinical Practice to Advance Real-World Evidence Utilization
Debra Schaumberg
Kay Larholt
Elizabeth Apgar
Chris L. Pashos
Gigi Hirsch
Therapeutic Innovation & Regulatory Science, 2023, 57 : 472 - 475
[3] Real-world evaluation of NASH in US clinical practice: Underutilization of liver biopsy and liver
Lai, Michelle
Milligan, Scott
Wick, Nicole
Younossi, Zobair
Afdhal, Nezam
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E775 - E776
[4] REAL-WORLD EVALUATION OF NASH IN US CLINICAL PRACTICE: UNDERUTILIZATION OF LIVER BIOPSY AND LIVER IMAGING
Lai, Michelle
Milligan, Scott
Wick, Nicole M.
Younossi, Zobair M.
Afdhal, Nezam H.
GASTROENTEROLOGY, 2019, 156 (06) : S1223 - S1223
[5] NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settings
Schattenberg, Joern M.
Balp, Maria-Magdalena
Reinhart, Brenda
Tietz, Andreas
Regnier, Stephane A.
Capkun, Gorana
Ye, Qin
Loeffler, Juergen
Pedrosa, Marcos C.
Docherty, Matt
SCIENTIFIC REPORTS, 2023, 13 (01)
[6] NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settings
Jörn M. Schattenberg
Maria-Magdalena Balp
Brenda Reinhart
Andreas Tietz
Stephane A. Regnier
Gorana Capkun
Qin Ye
Jürgen Loeffler
Marcos C. Pedrosa
Matt Docherty
Scientific Reports, 13
[7] Exploring the Clinical Utility of Targeted MECP2 Testing in Real-World Practice
Kim, Soo Yeon
Woo, Hyewon
Lim, Byung Chan
Kim, Ki Joong
Chae, Jong-Hee
PEDIATRIC NEUROLOGY, 2024, 161 : 28 - 33
[8] Real-world concordance of clinical practice with ASCO and NCCN guidelines for EGFR/ALK testing in aNSCLC.
Ruggiero, John E.
Rughani, Jay
Neiman, Josh
Swanson, Steven
Revol, Cindy
Green, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
[9] ASSOCIATION OF FIB4 SCORE WITH DISEASE PROGRESSION IN REAL-WORLD POPULATIONS DIAGNOSED WITH NAFLD/NASH OR AT RISK OF NASH IN US CLINICAL PRACTICE
Lai, Michelle
Broestl, Jeremy
Frick, Andrew
Haubrich, Richard
Koch, Bruce
Milligan, Scott
Natha, Macky
Younossi, Zobair M.
Afdhal, Nezam H.
GASTROENTEROLOGY, 2020, 158 (06) : S1416 - S1416
[10] Association of FIB-4 score with disease progression in real-world populations diagnosed with NAFLD/NASH or at risk of NASH in US clinical practice
Lai, Michelle
Broestl, Jeremy
Frick, Andrew
Haubrich, Richard
Koch, Bruce
Milligan, Scott
Natha, Macky
Younossi, Zobair
Afdhal, Nezam
JOURNAL OF HEPATOLOGY, 2020, 73 : S159 - S159

← 1 2 3 →